Current Treatment Options in Oncology

, Volume 10, Issue 1–2, pp 54–66

Current Status on Biologic Therapies in the Treatment of Epithelial Ovarian Cancer

Gynecologic Tumors

Treatment of epithelial ovarian cancer generally involves surgical staging followed by chemotherapy with a combination of a platinum and a taxane-containing agent. However, a majority of patients recur and ultimately succumb to their cancer. Novel therapies that target specific pathways involved in ovarian tumorigenesis are rapidly emerging. In ovarian cancer, targeted therapies have focused on both the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) pathways. Single-agent bevacizumab, a VEGF inhibitor, demonstrated significant clinical activity in multiple phase II studies. Various combinations of cytotoxic and biologic agents with bevacizumab as well as newer anti-angiogenesis agents are being tested. In contrast, EGFR inhibitors have not shared the same clinical activity in epithelial ovarian cancers as compared to the VEGF inhibitors. Translational studies are needed to help design rational combinations of targeted agents and to help predict response to therapy.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Jemal A, Siegel R, Ward R, et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58 (2): 71-96. doi:10.3322/CA.2007.0010 PubMedCrossRefGoogle Scholar
  2. 2.
    Disaia PJ, Creasman WT. Epithelial ovarian cancer. In: Disaia PJ, Creasman WT editors. Clinical gynecologic oncology. 7th ed. St. Louis: Mosby-Year Book; 2007. p.313-67.Google Scholar
  3. 3.
    Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum-based chemotherapy: a southwest oncology group and gynecologic oncology group trial. J Clin Oncol 2003, 21(13): 2460-65. doi:10.1200/JCO.2003.07.013.PubMedCrossRefGoogle Scholar
  4. 4.
    Alberts DS, Liu PY, Hannigan EV, et al. (1996). Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335 (26): 1950-5. doi:10.1056/NEJM199612263352603 PubMedCrossRefGoogle Scholar
  5. 5.
    Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the gynecologic oncology group, southwestern oncology group, and eastern cooperative oncology group. J Clin Oncol 2001, 19(4): 1001-7.PubMedGoogle Scholar
  6. 6.
    Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006, 354 (1): 34-43. doi:10.1056/NEJMoa052985.PubMedCrossRefGoogle Scholar
  7. 7.
    Ozols RF, Bookman MA, du Bois A, et al. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol 2006, 103(1): 1-6. doi:10.1016/j.ygyno.2006.06.026.PubMedCrossRefGoogle Scholar
  8. 8.
    Bookman, MA, for the Gynecologic Cancer Intergroup. GOG0182-ICON5: 5 arm phase III randomized trial of paclitaxel and carboplatin vs combinations with gemcitabine, PEG-liposomal doxorubicin, or topotecan in patients with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. Proc Am Soc Clin Oncol 2006, 24(18s):5002Google Scholar
  9. 9.
    Ellis LM and Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008, 8(8): 579-91. doi:10.1038/nrc2403.PubMedCrossRefGoogle Scholar
  10. 10.
    Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350: 2335-42. doi:10.1056/NEJMoa032691.PubMedCrossRefGoogle Scholar
  11. 11.
    Sandler A, Gray R, Perry MC, et al. Paclitaxel carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355: 2542-50. doi:10.1056/NEJMoa061884.PubMedCrossRefGoogle Scholar
  12. 12.
    Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357: 2666-76. doi:10.1056/NEJMoa072113.PubMedCrossRefGoogle Scholar
  13. 13.••
    Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol 2007; 25(33): 5165-71. doi:10.1200/JCO.2007.11.5345.PubMedCrossRefGoogle Scholar
  14. 14.••
    Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz H, Oza AM. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret hospital phase II consortia. J Clin Oncol 2008; 26(1): 76-82. doi:10.1200/JCO.2007.12.1939.PubMedCrossRefGoogle Scholar
  15. 15.••
    Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25(33): 5180-86. doi:10.1200/JCO.2007.12.0782.PubMedCrossRefGoogle Scholar
  16. 16.
    Han ES and Monk BJ. Bevacizumab in the treatment of ovarian cancer. Expert rev Anticancer Ther 2007, 7(10): 1339-45. doi:10.1586/14737140.7.10.1339 PubMedCrossRefGoogle Scholar
  17. 17.•
    Nimeiri HS, Oza AM, Morgan RJ, et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II consortia. Gynecol Oncol 2008, 110(1): 49-55. doi:10.1016/j.ygyno.2008.02.009.PubMedCrossRefGoogle Scholar
  18. 18.•
    Azad NS, Posadas EM, and Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008, 26 (22): 3709-14. doi:10.1200/JCO.2007.10.8332.PubMedCrossRefGoogle Scholar
  19. 19.
    Han ES and Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 2007, 105 (1): 3-6. doi:10.1016/j.ygyno.2007.01.038.PubMedCrossRefGoogle Scholar
  20. 20.
    Hirte HW, Vidal L, Fleming GF, et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal, or fallopian tube cancer: final results of PMH, Chicago and California consortia trial. Proc Am Soc Clin Oncol 2008, 26: 5521.Google Scholar
  21. 21.•
    Downs LS, Judson PL, Argenta PA, et al. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer 2008, 112: 331-9. doi:10.1002/cncr.23164.PubMedCrossRefGoogle Scholar
  22. 22.
    Byrne AT, Ross L, Holash J, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003, 9(15): 5721-8.PubMedGoogle Scholar
  23. 23.
    Tew WP, Colombo N, Ray-Coquard I, et al. VEGF-Trap for patients with recurrent platinum-resistant epithelial ovarian cancer: preliminary results of a randomized, multicenter phase II study. Proc Am Soc Clin Oncol 2007, 25 (18S): 5508.Google Scholar
  24. 24.
    Bhaskar V, Fox M, Breinber D, et al. Volociximab, a chimeric integrin alpha5beta1 antibody inhibits the growth of VX2 tumors in rabbits. Invest New Drugs 2008, 26: 7-12. doi:10.1007/s10637-007-9078-z PubMedCrossRefGoogle Scholar
  25. 25.
    Delmonte A, Del Conte G, Sessa C, et al. Results from a phase 1/2 study of volociximab in combination with liposomal doxorubicin in relapsed advanced epithelial ovarian and primary peritoneal carcinoma. Proc Am Soc Clin Oncol 2008, 26: 16527.Google Scholar
  26. 26.
    Camidge DR, Eckhardt SG, Diab S, et al. A Phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody in patients with advanced cancer. Proc Am Soc Clin Oncol 2006, 24 (18S):3032.Google Scholar
  27. 27.
    Marshall J. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107(6): 1207-1218.PubMedCrossRefGoogle Scholar
  28. 28.•
    Gordon AN, Finkler N, Edwards RP, et al. Efficacy and safety of erlotinib HCL, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 2005, 15: 785-92. doi:10.1111/j.1525-1438.2005.00137.x PubMedCrossRefGoogle Scholar
  29. 29.•
    Schilder RJ, Sill MW, Chen X, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a gynecologic oncology group study. Clin Cancer Res 2005, 11(15): 5539-48. doi:10.1158/1078-0432.CCR-05-0462.PubMedCrossRefGoogle Scholar
  30. 30.
    Posadas EM, Liel MS, Kwitkowski V, et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 2007, 109 (7): 1323-30. doi:10.1002/cncr.22545.PubMedCrossRefGoogle Scholar
  31. 31.•
    Wagner U, du Bois A, Pfisterer J, et al. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy- a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol 2007, 105 (1): 132-7. doi:10.1016/j.ygyno.2006.10.053.PubMedCrossRefGoogle Scholar
  32. 32.•
    Campos S, Hamid O, Seiden MV, et al. Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol 2005, 23(24): 5597-5604. doi:10.1200/JCO.2005.08.091.PubMedCrossRefGoogle Scholar
  33. 33.
    Bookman MA, Darcy KM, Clarke-Pearson D, et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the gynecologic oncology group. J Clin Oncol 2003, 21: 283-90. doi:10.1200/JCO.2003.10.104.PubMedCrossRefGoogle Scholar
  34. 34.•
    Seiden MV, Burris HA, Matulonis U, et al. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol 2007, 104:727-31. doi:10.1016/j.ygyno.2006.10.019.PubMedCrossRefGoogle Scholar
  35. 35.•
    Gordon MS, Matei D, Aghajanian C, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006, 24(26): 4324-32. doi:10.1200/JCO.2005.05.4221.PubMedCrossRefGoogle Scholar
  36. 36.•
    Secord AA, Blessing JA, Armstrong DK, et al. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a gynecologic oncology group study. Gynecol Oncol 2008, 108: 493-99. doi:10.1016/j.ygyno.2007.11.029.PubMedCrossRefGoogle Scholar
  37. 37.•
    Konner J, Schilder RJ, DeRosa FA, et al. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol 2008, 110: 140-145. doi:10.1016/j.ygyno.2008.04.018.PubMedCrossRefGoogle Scholar
  38. 38.
    Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008, 7(10): 3129-40. doi:10.1158/1535-7163.MCT-08-0013.PubMedCrossRefGoogle Scholar
  39. 39.
    Welch S, Hirte H, Elit L, et al. (2007) CA125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib- a trial of the PMH phase II consortium. Proc Am Soc Clin Oncol 25(18): 5519.Google Scholar
  40. 40.
    Matei D, Sill MW, DeGeest K, Bristow RE. Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a gynecologic oncology group study. Proc Am Soc Clin Oncol 2008, 26: 5537.Google Scholar
  41. 41.•
    Coleman RL, Broaddus RR, Bodurka DC, et al. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 2006, 101: 126-31. doi:10.1016/j.ygyno.2005.09.041 PubMedCrossRefGoogle Scholar
  42. 42.•
    Alberts DS, Liu PY, Wilczynski SP, et al. Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). Int J Gynecol Cancer 2007, 17:784-88. doi:10.1111/j.1525-1438.2007.00882.x PubMedCrossRefGoogle Scholar
  43. 43.
    Posadas EM, Kwitkowski V, Kotz HL, et al. A prospective analysis of imatinib-induced c-kit modulation in ovarian cancer. 2007, 110(2): 309-317.PubMedCrossRefGoogle Scholar
  44. 44.•
    Schilder RJ, Sill MW, Lee RB, et al. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. J Clin Oncol 2008, 26(20): 3418-25. doi:10.1200/JCO.2007.14.3420.PubMedCrossRefGoogle Scholar
  45. 45.•
    Matei D, Emerson RE, Schilder J, et al. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis. Cancer 2008, 113 (4): 723-32. doi:10.1002/cncr.23605.PubMedCrossRefGoogle Scholar
  46. 46.
    Le Tourneau C, Fairvre S, and Raymond E. New developments in multitargeted therapy for patients with solid tumours. Cancer Treat Rev 2008, 34(1): 37-48. doi:10.1016/j.ctrv.2007.09.003 PubMedCrossRefGoogle Scholar
  47. 47.
    Wong F, Reeves K, Han X, et al. Sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007, 67 (5): 2226-38. doi:10.1158/0008-5472.CAN-06-3633.PubMedCrossRefGoogle Scholar
  48. 48.
    Hotte SJ, Hirte HW, Chen EX, et al. A phase I study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 2008, 14(11): 3450-55. doi:10.1158/1078-0432.CCR-07-1416.PubMedCrossRefGoogle Scholar
  49. 49.
    Coppola D, Saunders B, Fu L et al. The insulin-like growth factor 1 receptor induces transformation and tumorgenicity of ovarian mesothelial cells and down-regulates their Fas-receptor expression. Cancer Res 1999, 59(13): 3264-70.PubMedGoogle Scholar
  50. 50.
    Beltran PJ, Mitchell P, Moody G, et al. Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models. Proc Am Soc Clin Oncol 2008, 26 (15s): 4617.Google Scholar
  51. 51.•
    Coleman, RL and Kohn EC. Rationale for combination use of targeted agents in ovarian cancer. Cancer 2008, 113(4): 665-7. doi:10.1002/cncr.23604.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Division of Gynecologic Oncology, Department of SurgeryCity of HopeDuarteUSA

Personalised recommendations